INTRODUCTION
Breast cancer is the most prevalent cancer in woman worldwide. In Korea, breast cancer accounts for 37.3% of all cancers in women and is 6th as a cause of cancerrelated death. The incidence rate represents an upward trend that has continued to increase by more than 6.8% per year since 1999. (1) This trend is expected to progress due to early detection and westernized lifestyles. Unfortunately, the severe morbidity of these cancers, reflected in the poor 5-yr relative survival rate, has not been improved by current treatments that include surgery, radiotherapy, hormone therapy, and adjuvant chemotherapies. (2) Although breast cancer research has developed at a rapid pace over the last decade, the curative potential of currently available therapies remains disappointing. Thus, there is a need for ongoing research into the development of new breast cancer therapeutic approaches.
The immune system is capable of recognizing and rejecting autologous tumor cells, as suggested by cases of spontaneous remission of various cancers, (3) and the presence of infiltrating leukocytes, the majority of which consist of T cells.(4) Furthermore, there is a direct correlation between immunosuppresion and increased incidence of certain malignancies, e.g., Epstein-Barr virus (EBV)associated lymphomas, Kaposi' s sarcoma, and cervical cancer.(5) However, the very existence of cancer and its inevitable progression without treatment demonstrate the inefficiency of natural defense against tumors, and the ability of neoplastic cells to evade immune-surveillance. Thus, the major objective of cancer immunotherapeutic approaches is to augment the effectiveness and efficiency of the immune response against malignant Many breast cancer patients develop minimal residual disease that becomes resistance to treatments, and finally are faced with relapse and progression of disease. Currently, immunotherapy has become a potential therapy in treating minimal residual disease and preventing cancer occurrence. Cancer vaccines provide a unique therapeutic modality in that they initiate a dynamic process of activating the host's own immune system. A lot of tumor specific antigens as a target of immune system were identified and some have been applied for cancer vaccine. Mucin 1 (MUC1) oncoprotein, which is overexpressed in breast cancer in contrast with normal mammary tissue, is one of the first tumor antigens shown to be a target for human tumor-specific T cells and thus a valid target for immunotherapy. MUC1 is a high-molecular-weight glyco-protein rich in serine and threonine residues that are O-glycosylated. MUC1 is expressed on glandular epithelia and on epithelial tumors. But, tumor MUC1 differs from normal MUC1 by modified glycan side chains. Over-expression and aberrant glycosylation of MUC1 antigen by epithelial tumors results in endogenous antibody responses in cancer patients to MUC1 antigen. This finding has led to the identification of MUC1 derived peptide epitopes that induce T-cell responses. MUC1 based clinical trials have used peptides, protein, DNA, pulsed dendritic cells, or glycopeptide. This review will summarize the potential utility of breast cancer immunotherapy of MUC1, as well as the structure and function.
tissues.
Cancer vaccines provide a unique therapeutic modality in that they initiate a dynamic process of activating the host' s own immune system. This process has the potential to change the patient' s initial responses, and responses to subsequent therapies after vaccination, are evaluated.
Recent preclinical and clinical findings have shown that well-designed clinical trials with appropriate endpoints, as well as administration of vaccines in new paradigms for combination therapies, may ultimately lead to the use of cancer vaccines for treatment of many types of cancer. Mucin 1 (MUC1) is one of the first tumor antigens shown to be a target for human tumor-specific T cells and thus a valid target for immunotherapy. MUC1 is a member of the mucin family of molecules.
Mucins encompass a family of high molecular weight, 
IMMUNOTHERAPEUTIC APPLICATIONS WITH MUC1
In patients with cancer hypoglycosylation of the MUC1 protein core exposes an immunodominant repetitive amino acid sequence that is masked in healthy individuals. (14) Cellular immune responses to MUC1 have been document- 
PEPTIDE-BASED VACCINES
Vaccines based on synthetic peptides have the advantage of being readily available, although they require identification of the exact epitope recognized by T or B cells. Most peptide vaccines have been tested for their ability to elicit strong CTL responses; however, optimal vaccine formulations should also include one or more antigen-specific T helper epitope. Helper responses to MUC1 have not been detected to date in cancer patients.
Therefore, identification of MUC1-derived helper epitopes and testing such epitopes in vivo are of crucial importance and need to be further addressed.
A vaccine consisting of a single tandem-repeat peptide of MUC1 (20 amino-acids) conjugated to diphtheria toxoid has been assessed for safety in a phase I trial. (63) No MUC1-related toxicity was noted in this study, although the preparation did not appear to be highly immunogenic.
In 
DNA-BASED VACCINES
The concept of DNA-based vaccine is the cellular uptake of cDNA, which results in antigen expression followed 
CONCLUSION
The mucin family has considerable potential importance in the biology, diagnosis, and treatment of malignancy.
In particular, MUC1 can act as a target and as a tumor 
